Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance

  • Baek, Dong Won (Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University) ;
  • Park, Ji-Young (Kyungpook National University Cancer Research Institute) ;
  • Lee, Soo Jung (Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University) ;
  • Chae, Yee Soo (Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University)
  • 투고 : 2019.11.14
  • 심사 : 2019.12.23
  • 발행 : 2020.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Systemic therapy for metastatic triple-negative breast cancer (TNBC) still remains challenging because there are no targeted agents or endocrine therapies currently available. The present case report documents the successful use of cisplatin monotherapy to manage a heavily pretreated TNBC patient showing poor response to therapy. The patient was a 51-year-old woman who had already undergone several lines of systemic chemotherapy for widespread TNBC. Although the mutation analysis performed on DNA isolated from blood cells and progressed lesion samples confirmed the tumor to be germline BRCA wild-type, cisplatin monotherapy was administered based on the increasing evidence of safety and efficacy of platinum for breast cancer. After three cycles of cisplatin treatment, the patient's metastatic lesions dramatically improved without any major toxicity, and she completed 17 cycles with good response. This case study indicates that patients with heavily pretreated TNBC can potentially achieve a good response to cisplatin monotherapy.

키워드

참고문헌

  1. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010;15(Suppl 5):39-48. https://doi.org/10.1634/theoncologist.2010-S5-39
  2. O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, et al. Therapeutic targets in triple negative breast cancer. J Clin Pathol 2013;66:530-42. https://doi.org/10.1136/jclinpath-2012-201361
  3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. https://doi.org/10.1158/1078-0432.CCR-06-3045
  4. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523-33. https://doi.org/10.1056/NEJMoa1706450
  5. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379:753-63. https://doi.org/10.1056/NEJMoa1802905
  6. Mersin H, Yildirim E, Berberoglu U, Gulben K. The prognostic importance of triple negative breast carcinoma. Breast 2008;17:341-6. https://doi.org/10.1016/j.breast.2007.11.031
  7. National Comprehensive Cancer Network (NCCN). NCCN guidelines: breast cancer (version 3.2019) [Internet]. Plymouth Meeting (PA): NCCN; 2019 [cited 2019 Dec 23]. https://www.nccn.org.
  8. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-72. https://doi.org/10.1016/S0140-6736(13)62422-8
  9. Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 2011;3:1351-71. https://doi.org/10.3390/cancers3011351
  10. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:1847-52. https://doi.org/10.1093/annonc/mdn395
  11. Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010;19:246-8. https://doi.org/10.1016/j.breast.2010.02.003
  12. Agrawal LS, Mayer IA. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice? Clin Adv Hematol Oncol 2014;12:654-8.
  13. Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011;22:848-56. https://doi.org/10.1093/annonc/mdq461
  14. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015;33:1902-9. https://doi.org/10.1200/JCO.2014.57.6660
  15. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53. https://doi.org/10.1200/JCO.2009.22.4725
  16. Cortesi L, Masini C, Cirilli C, Medici V, Marchi I, Cavazzini G, et al. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer 2010;10:90. https://doi.org/10.1186/1471-2407-10-90
  17. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, et al. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010;70:1700-10. https://doi.org/10.1158/0008-5472.CAN-09-3367
  18. Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol 2017;3:1378-85. https://doi.org/10.1001/jamaoncol.2017.1007
  19. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016;22:3764-73. https://doi.org/10.1158/1078-0432.CCR-15-2477
  20. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med 2018;24:628-37. https://doi.org/10.1038/s41591-018-0009-7

피인용 문헌

  1. Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review vol.21, pp.20, 2020, https://doi.org/10.3390/ijms21207753